Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Kaoru Kubota"'
Autor:
Tae Iwasawa, Takaaki Tokito, Hirotsugu Kenmotsu, Shinobu Hosokawa, Takeharu Yamanaka, Satoshi Ikeda, Shunichiro Iwasawa, Yuki Sato, Kaoru Kubota, Hiroaki Okamoto, Toshihide Yokoyama, Isamu Okamoto, Takashi Ogura, Naoki Furuya, Terufumi Kato, Toshiyuki Harada
Publikováno v:
Journal of Thoracic Oncology
Introduction Interstitial pneumonia (IP) is one of the most common and poor prognostic comorbidities in patients with NSCLC and a known risk factor for pneumonitis. Atezolizumab monotherapy is an established treatment for recurrent NSCLC and reported
Autor:
Kaoru Kubota, Masaru Nishitsuji, Masahiro Seike, Koichi Hagiwara, Masahiro Ando, Makiko Yomota, Akihiko Miyanaga, Mitsunori Hino, Tsuneo Shimokawa, Rintaro Noro, Akihiko Gemma, Jiro Usuki, Kunihiko Kobayashi
Publikováno v:
Thoracic Cancer. 11:1876-1884
Background Pleurodesis is the standard of care for non-small cell lung cancer (NSCLC) patients with symptomatic malignant pleural effusion (MPE). However, there is no standard management for MPE uncontrolled by pleurodesis. Most patients with unsucce
Autor:
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko, Kaoru Kubota, Gregory M Lubiniecki, Jin Zhang, Debra Kush, Gilberto Lopes, Grigory Adamchuk, Myung-Ju Ahn, Aurelia Alexandru, Ozden Altundag, Anna Alyasova, Orest Andrusenko, Keisuke Aoe, Antonio Araujo, Osvaldo Aren, Oscar Arrieta Rodriguez, Touch Ativitavas, Oscar Avendano, Fernando Barata, Carlos Henrique Barrios, Carlos Beato, Per Bergstrom, Daniel Betticher, Larisa Bolotina, Michiel Botha, Sayeuri Buddu, Christian Caglevic, Andres Cardona, Hugo Castro, Filiz Cay Senler, Carlos Alexandre Sydow Cerny, Alvydas Cesas, Gee-Chen Chan, Jianhua Chang, Gongyan Chen, Xi Chen, Susanna Cheng, Ying Cheng, Nelly Cherciu, Chao-Hua Chiu, Saulius Cicenas, Daniel Ciurescu, Graham Cohen, Marcos Andre Costa, Pongwut Danchaivijitr, Flavia De Angelis, Sergio Jobim de Azevedo, Mircea Dediu, Tsvetan Deliverski, Pedro Rafael Martins De Marchi, Flor de The Bustamante Valles, Zhenyu Ding, Boyan Doganov, Lydia Dreosti, Ricardo Duarte, Regina Edusma-Dy, Sergey Emelyanov, Mustafa Erman, Yun Fan, Luis Fein, Jifeng Feng, David Fenton, Gustavo Fernandes, Carlos Ferreira, Fabio Andre Franke, Helano Freitas, Yasuhito Fujisaka, Hector Galindo, Christina Galvez, Doina Ganea, Nuno Gil, Gustavo Girotto, Erdem Goker, Tuncay Goksel, Gonzalo Gomez Aubin, Luis Gomez Wolff, Hakan Griph, Mahmut Gumus, Jacqueline Hall, Gregory Hart, Libor Havel, Jianxing He, Yong He, Carlos Hernandez Hernandez, Venceslau Hespanhol, Tomonori Hirashima, Chung Man James Ho, Atsushi Horiike, Yukio Hosomi, Katsuyuki Hotta, Mei Hou, Soon Hin How, Te-Chun Hsia, Yi Hu, Masao Ichiki, Fumio Imamura, Oleksandr Ivashchuk, Yasuo Iwamoto, Jana Jaal, Jacek Jassem, Christa Jordaan, Rosalyn Anne Juergens, Diego Kaen, Ewa Kalinka-Warzocha, Nina Karaseva, Boguslawa Karaszewska, Andrzej Kazarnowicz, Kazuo Kasahara, Nobuyuki Katakami, Terufumi Kato, Tomoya Kawaguchi, Joo Hang Kim, Kazuma Kishi, Vitezslav Kolek, Marchela Koleva, Petr Kolman, Leona Koubkova, Ruben Kowalyszyn, Dariusz Kowalski, Krassimir Koynov, Doran Ksienski, Takayasu Kurata, Gerli Kuusk, Lyudmila Kuzina, Ibolya Laczo, Guia Elena Imelda Ladrera, Konstantin Laktionov, Gregory Landers, Sergey Lazarev, Guillermo Lerzo, Krzysztof Lesniewski Kmak, Wei Li, Chong Kin Liam, Igor Lifirenko, Oleg Lipatov, Xiaoqing Liu, Zhe Liu, Sing Hung Lo, Valeria Lopes, Karla Lopez, Shun Lu, Gaston Martinengo, Luis Mas, Marina Matrosova, Rumyana Micheva, Zhasmina Milanova, Lucian Miron, Tony Mok, Matias Molina, Shuji Murakami, Yasuharu Nakahara, Tien Quang Nguyen, Takashi Nishimura, Adrian Ochsenbein, Tatsuo Ohira, Ronny Ohman, Choo Khoon Ong, Gyula Ostoros, Xuenong Ouyang, Elena Ovchinnikova, Ozgur Ozyilkan, Lubos Petruzelka, Xuan Dung Pham, Pablo Picon, Bela Piko, Artem Poltoratsky, Olga Ponomarova, Patrice Popelkova, Gunta Purkalne, Shukui Qin, Rodryg Ramlau, Bernardo Rappaport, Felipe Rey, Eduardo Richardet, Jaromir Roubec, Paul Ruff, Andrii Rusyn, Hideo Saka, Jorge Salas, Mario Sandoval, Lucas Santos, Toshiyuki Sawa, Kasan Seetalarom, Mesut Seker, Nobuhiko Seki, Freddy Seolwane, Lucinda Shepherd, Sergii Shevnya, Andrea Kazumi Shimada, Yaroslav Shparyk, Ivan Sinielnikov, Daniela Sirbu, Oren Smaletz, Joao Paulo Holanda Soares, Aumkhae Sookprasert, Giovanna Speranza, Virote Sriuranpong, Zinaida Stara, Wu-Chou Su, Shunichi Sugawara, Waldemar Szpak, Kazuhisa Takahashi, Nagio Takigawa, Hiroshi Tanaka, Jerry Tan Chun Bing, Qiyou Tang, Pavel Taranov, Hermes Tejada, Lye Mun Tho, Yoshitaro Torii, Dmytro Trukhyn, Maria Turdean, Hande Turna, Grygoriy Ursol, Jaroslav Vanasek, Mirta Varela, Marcela Vallejo, Luis Vera, Ana-Paula Victorino, Tomas Vlasek, Ihor Vynnychenko, Buhai Wang, Jie Wang, Kai Wang, Yilong Wu, Kazuhiko Yamada, Chih-Hsin Yang, Takuma Yokoyama, Toshihide Yokoyama, Hiroshige Yoshioka, Fulden Yumuk, Angela Zambrano, Juan Jose Zarba, Oleg Zarubenkov, Marius Zemaitis, Li Zhang, Xin Zhang, Jun Zhao, Caicun Zhou, Jianying Zhou, Qing Zhou, Alfred Zippelius
Publikováno v:
The Lancet. 393:1819-1830
Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater.
Autor:
Kaoru Kubota, Yuichiro Ohe, Hidetoshi Hayashi, Tomohide Tamura, Tsuneo Shimokawa, Makoto Nishio, Toyoaki Hida, Tomohisa Baba, Kazutaka Miyadera, Kazuo Kasahara, Haruyasu Murakami, Hiroshi Sakai, Fumio Imamura, Yukio Hosomi
Publikováno v:
Investigational New Drugs
Summary Purpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients wit
Autor:
Norihiko Ikeda, Toshiaki Saeki, Fumiyoshi Ohyanagi, Tomohide Tamura, Yutaka Tokuda, Kenichi Inoue, Hiroshi Sakai, Hiroshi Kagamu, Kaoru Kubota, Koichi Minato, Akihiko Osaki, Kazuhiko Yamada
Publikováno v:
Japanese Journal of Clinical Oncology. 49:121-129
Objective Netupitant is a novel, selective neurokinin-1 receptor antagonist used for prevention of chemotherapy-induced nausea and vomiting, a distressing side effect of chemotherapy. This double-blind, randomized, Phase II study investigated the dos
Autor:
Sergey Orlov, Kaoru Kubota, Jesús Cárdenas Sánchez, Jin-Hyoung Kang, Li Zhang, Alexander N. Fleishman, Joseph K. Park, Vera Hirsh, Konstantinos N. Syrigos, Carlos H. Barrios, Gary Thomas, David H. Henry, Cisio De Oliveira Brandao, Tilman Steinmetz, Dianne Tomita, Pere Gascón, Martin Šmakal, Rajnish Nagarkar, David Gordon
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 15(2)
This study evaluated noninferiority of darbepoetin alfa versus placebo for overall survival (OS) and progression-free survival (PFS) in anemic patients with NSCLC treated to a 12.0-g/dL hemoglobin (Hb) ceiling.Adults with stage IV NSCLC expected to r
Autor:
Yuji Minegishi, Tomomi Kato, Yoshinobu Saito, Kenichiro Atsumi, Masahiro Seike, Akihiko Gemma, Yasuhiro Terasaki, Kaoru Kubota, Takeru Kashiwada
Publikováno v:
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi. 86(1)
Acute exacerbation of pre-existing interstitial lung disease (ILD) associated with systemic anticancer therapy is recognized as a life-threatening adverse event of lung cancer treatment. Programmed cell death 1 (PD-1) checkpoint inhibitors, such as n
Autor:
Asuka Nakanishi, Rintaro Noro, Akihiko Gemma, Toru Tanaka, Hidehisa Saeki, Ken Okamura, Yoko Funasaka, Mai Yoshida, Yuji Minegishi, Susumu Takeuchi, Ryoko Takayama, Masahiro Seike, Teppei Sugano, Kaoru Kubota
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induce various immune-related adver
Autor:
Rintaro Noro, Kakeru Hisakane, Takehiro Tozuka, Yoshinobu Saito, Satoshi Takahashi, Natsuki Takano, Takeru Kashiwada, Kaoru Kubota, Yuji Minegishi, Masahiro Seike, Susumu Takeuchi, Toru Tanaka, Akihiko Gemma, Shinobu Kunugi, Teppei Sugano
Publikováno v:
Oxford Medical Case Reports
An 82-year-old man with a recurrence of pulmonary pleomorphic carcinoma was treated with pembrolizumab. He achieved partial response after three cycles of pembrolizumab. However, he developed febrile neutropenia. A bone marrow aspiration sample revea
Autor:
Kaoru Kubota, Rintaro Noro, Kakeru Hisakane, Akihiko Miyanaga, Akihiko Gemma, Susumu Takeuchi, Yoshinobu Saito, Teppei Sugano, Takeru Kashiwada, Yuji Minegishi, Masahiro Seike, Yasuhiro Terasaki
Publikováno v:
Japanese journal of clinical oncology. 49(2)
Background Nanoparticle albumin-bound paclitaxel is indicated for the treatment of patients with lung cancer. It can induce interstitial lung disease, but the incidence of nanoparticle albumin-bound paclitaxel-associated interstitial lung disease in